Active Ingredient History

  • Now
Dolutegravir is an integrase inhibitor that is meant to be used as part of combination therapy for the treatment of HIV. Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Dolutegravir coadministered with dofetilide can result in potentially life-threatening adverse events.   NCATS

  • SMILES: C[C@@H]1CCO[C@H]2CN3C=C(C(=O)NCc4ccc(F)cc4F)C(=O)C(=C3C(=O)N12)O
  • Mol. Mass: 419.38
  • ALogP: 1.35
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$4.5562 - $62.0679


More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( dolutegravir (tivicay), lamivudine (epivir) - other names: dolutegravir 50 mg / lamivudine 300 mg oral tablet [dovato], dolutegravir/lamivudine, dolutegravir/lamivudine 50 mg-300 mg oral tablet [dovato], dolutegravir/lamivudine as a single pill, dolutegravir / lamivudine oral tablet, dolutegravir plus lamivudine in a fdc )
| |
2h-pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9- carboxamide, n-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a- hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4r,12as)- | (4r,9as)-5-hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2h-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide | abacavir sulfate / dolutegravir sodium / lamivudine | dolutegravir | dolutegravir sodium | dolutegravir sodium monohydrate | gsk1349572 | gsk 1349572 | gsk-1349572 | gsk1349572a | gsk 1349572a | s-349572 | s-gsk1349572 | tivicay


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue